Merger to create a company focused on advancing Oruka’s portfolio of novel biologics that aim to redefine the standard of care for patients with chronic skin diseases
Oruka, the third company founded based on assets generated by Paragon Therapeutics, expects to advance ORKA-001 and ORKA-002, potentially best-in-class antibodies targeting IL-23p19 and IL-17A/F, respectively, into clinical trials in 2025
Pre-closing private financing of approximately $275 million anticipated to fund operations through 2027
Companies to hold conference call on April 3, 2024 at 8:30 AM EDT
he companies plan to hold a joint conference call on April 3, 2024 at 8:30 AM EDT to discuss the merger details.
The dial-in number in the U.S./Canada is (800) 715-9871; for international participants, the number is (646) 307-1963. For all callers, please refer to the Conference ID 4737644.
Live webcast link: https://edge.media-server.com/mmc/p/rnug3oyp
A replay of the conference call will be available for seven business days beginning shortly after the conclusion of the live call, by calling: Toll Free: (800) 770-2030; Toll: (609) 800-9909; Playback ID: 4737644#.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.